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We  conducted  a randomized,  controlled,  multicenter,  phase  II study  to  evaluate  the  immunogenicity
and  safety  of  an  investigational  intradermal  (ID)  trivalent  inﬂuenza  vaccine  (TIV)  and  a high-dose  (HD)
intramuscular  (IM)  TIV  in older  adults  (≥65  years  of  age).  Older  adult  subjects  were  immunized  with  ID
vaccine  containing  either  15 g hemagglutinin  (HA)/strain  (n = 636)  or 21  g  HA/strain  (n =  634),  with
HD  IM  vaccine  containing  60 g HA/strain  (n = 320),  or with  standard-dose  (SD)  IM  vaccine  (Fluzone®;
15  g HA/strain;  n  =  319).  For  comparison,  younger  adults  (18–49  years  of age)  were  immunized  with
SD  IM vaccine.  In older  adults,  post-vaccination  geometric  mean  titers  induced  by the  ID vaccines  were
superior  to those  induced  by the  SD  IM vaccine  for  the  A/H1N1  and A/H3N2  strains  and  non-inferior
for  the B strain.  Seroconversion  rates  induced  by  the ID  vaccines  were  superior  to those  induced  by
the  SD  IM  vaccine  in older  adults  for  the  A/H1N1  and  B strains  and  non-inferior  for  the  A/H3N2  strain.
Results  did  not  differ  signiﬁcantly  for the  two  ID vaccine  dosages.  Post-vaccination  geometric  mean  titers,
seroconversion  rates,  and  most seroprotection  rates  were  signiﬁcantly  higher  in HD vaccine  recipients
than  in  older  adult  recipients  of  the SD  IM  or  ID  vaccines  and,  for  most  measures,  were  comparable
to  those  of  younger  adult SD  IM vaccine  recipients.  Injection-site  reactions,  but not  systemic  reactions
or  unsolicited  adverse  events,  were  more  common  with  the  ID  vaccines  than  with  the  IM vaccines.  No
treatment-related  serious  adverse  events  were  reported.  This  study  demonstrated  that:  (1)  the  ID and
HD  vaccines  were  well-tolerated  and  more  immunogenic  than  the  SD  IM  vaccine  in older  adults;  (2) the
HD  vaccine  was  more  immunogenic  than  the ID vaccines  in older  adults;  and  (3)  the  HD vaccine  in older
adults  and  the  SD  IM  vaccine  in younger  adults  elicited  comparable  antibody  responses  (ClinicalTrials.gov
identiﬁer  no.: NCT00551031).
© 2014  The  Authors.  Published  by Elsevier  Ltd.  Open access under CC BY-NC-ND license.Abbreviations: AE, adverse event; CI, conﬁdence interval; GMT, geometric mean
iter; HA, hemagglutinin; HI, hemagglutination inhibition; HD, high-dose inactiv-
ted trivalent inﬂuenza vaccine (60 g HA/strain) for the intramuscular route; ID,
ntradermal; IM,  intramuscular; SD, standard-dose inactivated trivalent inﬂuenza
accine  (15 g HA/strain) for the intramuscular route.
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Open access under CC BY-NC-ND 1. Introduction
Despite progressive increases in seasonal inﬂuenza vaccine cov-
erage, inﬂuenza-related morbidity, mortality, and hospitalization
rates remain high and have continued to increase in older adults
(≥65 years of age) [1]. Up to 90% of all annual inﬂuenza-related
deaths occur in the older adults [2], whose aging immune systems
respond weakly to vaccines and are less able to combat infection
[1,3–5]. Consequently, more effective vaccines are needed to pre-
vent inﬂuenza in older adults.
Intradermal (ID) vaccines are an alternative to intramus-
cular (IM) vaccines that may  offer improved immunogenicity
in older adults [6]. ID vaccination exploits the numerous
license.
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ntigen-presenting dendritic cells, macrophages, and T-cells
resent in the skin as well as its dense network of lymphatic and
lood vessels [7–9]. These features enable strong innate and adap-
ive immune responses to be generated following ID exposure
o vaccine antigens [10,11]. In addition, new microinjection sys-
ems have made routine ID vaccine administration feasible [7,12].
luzone® Intradermal (Sanoﬁ Pasteur, Swiftwater, PA) is an inactiv-
ted split-virion trivalent inﬂuenza vaccine (TIV) that is delivered
ith the BD SoluviaTM microinjection system (BD, Franklin Lakes,
J) and licensed in the US for use in adults 18–64 years of age.
 phase II study in this age group showed that the 9 g formu-
ation (9 g hemagglutinin [HA]/strain) of this vaccine induced
on-inferior immune responses compared to the standard 15 g
ormulation of Fluzone TIV delivered by the IM route [13]. The
mmunogenicity and safety of ID inﬂuenza vaccine in older adults
≥65 years old) in the US has not been previously established. How-
ver, in Europe, phase II and III studies with Intanza®/IDﬂu® (Sanoﬁ
asteur, Lyon, France), a similar ID TIV licensed in Europe and
lso administered with the BD Soluvia microinjection system, indi-
ated superior immunogenicity of the 15 and 21 g formulations
ompared to the standard 15 g formulation of TIV (Vaxigrip®)
elivered by the IM route in adults ≥60 years of age [14,15].
Increasing the HA dose in IM vaccines is another approach to
mprove vaccine-induced immune responses. In the US, standard-
ose TIV for the IM route (SD) contains 15 g HA per strain for all
ersons at least 36 months of age [16]. In 2009, the US Food & Drug
dministration approved a high-dose TIV for the IM route (HD) that
ontains 60 g HA per strain (Fluzone® High-Dose, Sanoﬁ Pasteur,
wiftwater, PA) [17]. This HD vaccine was licensed in older adults
ased on the results of a phase III clinical trial in which it induced
eometric mean antibody titers (GMTs) and seroconversion rates
uperior to those of the SD vaccine [18]. However, whether the HD
accine in older adults can elicit responses similar to those induced
y the SD vaccine in younger adults has not been determined.
Here,  we report the results of a phase II study conducted in
he US during the 2007/2008 inﬂuenza season to assess the safety,
mmunogenicity, and acceptability of 15 and 21 g formulations of
D vaccine and of HD IM vaccine in older adults compared to SD IM
accine in older and younger adults.
. Materials and methods
.1.  Study design
This  study was a phase II, multicenter, ﬁve-arm, randomized,
ontrolled trial examining the safety, immunogenicity, and accept-
bility of two investigational ID vaccines (15 and 21 g HA/dose),
D vaccine (60 g HA/dose), and SD vaccine (15 g HA/dose) in
lder adults (≥65 years of age) compared to SD vaccine in younger
dults (18–49 years of age) (ClinicalTrials.gov ID: NCT00551031).
he four study arms in older adult subjects were double-blinded for
ose but open-label for vaccination route, whereas the ﬁfth arm in
ounger adults was open-label. The primary objectives of the study
ere to demonstrate that the GMTs and seroconversion rates of
ach ID vaccine in older adults were: (i) non-inferior to those of the
D vaccine in older adults for each immunizing strain and (ii) supe-
ior to those of the SD vaccine for at least two of the three strains
nce non-inferiority was demonstrated. The secondary objectives
f the study were to describe: (i) the post-vaccination seroconver-
ion rates and GMTs of older adult HD vaccine recipients compared
o those of younger adult SD vaccine recipients; (ii) the seroprotec-
ion rates of all groups; and (iii) the safety proﬁles of the vaccines
n all groups.
The  study was performed at 31 centers in the US between
ctober 24, 2007 and June 2, 2008. The study was approved by a (2014) 2507–2517
central institutional review board and ﬁve local institutional review
boards and was  conducted in accordance with the Edinburgh revi-
sion of the Declaration of Helsinki and International Conference on
Harmonization Good Clinical Practice and Good Laboratory Practice
guidelines. All subjects provided written informed consent before
being enrolled in the trial.
2.2.  Subjects
Subjects were medically stable, ambulatory, older adults (≥65
years of age) or younger adults (18–49 years of age). Women could
not be pregnant or breastfeeding and if of child-bearing poten-
tial had to be using an effective method of contraception within
4 weeks before and after vaccination. Subjects were excluded if they
had any of the following: known sensitivity to any of the vaccine
components or to inﬂuenza vaccine; vaccinated against inﬂuenza
within 6 months or any other vaccination within 4 weeks; history of
Guillain-Barré syndrome; known or suspected immunodeﬁciency;
immunosuppressive therapy within 6 months or long-term sys-
temic corticosteroid therapy for more than 2 consecutive weeks
within 3 months; bleeding disorder or received anticoagulants
within 3 weeks; seropositive for human immunodeﬁciency virus,
hepatitis B, or hepatitis C; received blood or blood-derived prod-
ucts within 3 months; or any other disease, condition, or treatment
that might, in the opinion of the investigator, interfere with the
assessment of immune responses or blood sample collection.
Target  enrollment in older adult subjects was 600 for each of
the ID vaccine groups, 300 for the SD vaccine group, and 300 for
the HD vaccine group. Target enrollment for the younger adult SD
group was  150. Assuming a drop-out rate of 5% and based on data
from similar studies comparing ID and IM TIVs [14,15], at  ˛ = 0.05,
the power to meet the primary objectives for the 15 g ID vaccine
was 95.2% for the H1N1 strain, 98.6% for the H3N2 strain, and 71.6%
for the B strain, and for the 21 g ID vaccine, was >99.9% for each of
the three strains. With these enrollment targets, safety events that
occurred in 2% of 150 subjects, 1% of 300 subjects, and in 0.5% of
600 subjects were detectable with a probability of 0.95.
2.3.  Vaccines
All  vaccines were formulated as recommended by the US
Food and Drug Administration for the 2007/2008 inﬂuenza
season and contained the A/Solomon Islands/3/2006 (H1N1),
A/Wisconsin/67/2005 (H3N2), and B/Malaysia/2506/2004 strains.
The investigational ID vaccines were manufactured by Sanoﬁ Pas-
teur (Swiftwater, PA) and contained either 15 g (batch UD09995)
or 21 g (batch UD09996) of HA per strain in 0.1 mL  in a preﬁlled BD
Soluvia microinjection device bearing a staked 30-gauge, 1.5 mm
intradermal needle. The HD vaccine (Sanoﬁ Pasteur, Swiftwater, PA;
batch UD09997) contained 60 g of HA per strain and the SD vac-
cine (Fluzone®, Sanoﬁ Pasteur, Swiftwater, PA; older adults, batch
UD10002; adults, batch UD09999) contained 15 g of HA per strain
in ready-to-use 0.5-mL syringes and were delivered by the IM route.
2.4. Treatments
Older adult subjects (≥65 years of age) were randomized 2:2:1:1
using an interactive computer system to receive a single dose of the
15 g ID vaccine, the 21 g ID vaccine, HD vaccine, or SD vaccine.
All younger adult subjects were assigned to receive the SD vaccine.
All vaccines were administered into the deltoid area of the upper
arm.2.5. Immunogenicity
Blood samples were collected before vaccination (day 0) and
28 days after vaccination. Hemagglutination inhibition (HI) titers
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ere measured using a standard assay [19]. The serum HI antibody
iter was deﬁned as the reciprocal of the highest serum dilution that
ompletely inhibited hemagglutination. To calculate GMTs, sam-
les with HI not reaching 100% at the lowest serum dilution tested
1:10) were assigned a titer of 5. Seroconversion in a subject was
eﬁned by either a pre-vaccination HI titer <1:10 and a day-28 titer
1:40 or by a pre-vaccination titer ≥1:10 and a minimum four-fold
iter increase at day 28. Seroprotection was deﬁned as a pre- or
ost-vaccination HI titer ≥1:40.
.6. Safety and reactogenicity
Adverse  events (AEs) were recorded according to the Inter-
ational Conference on Harmonization Guideline for Clinical
afety Data Management: Deﬁnitions and Standards for Expe-
ited Reporting [20]. Solicited systemic reactions (fever, headache,
alaise, myalgia, and chills) and solicited injection-site reactions
pain, erythema, swelling, induration, ecchymosis, and pruritus)
ere recorded by subjects on diary cards for up to 7 days follow-
ng vaccination. Other non-serious unsolicited AEs were recorded
y patients up to 28 days after vaccination. Serious adverse events
ere recorded by investigators up to 6 months after vaccination.
njection-site erythema, swelling, induration, and ecchymosis were
onsidered grade 1 if <2.5 cm,  grade 2 if ≥2.5 to <5 cm,  and grade
 if ≥5 cm.  Fever was considered grade 1 if ≥99.5 ◦F and ≤100.4 ◦F
≥37.5 ◦C to ≤38 ◦C), grade 2 if >100.4 ◦F and ≤102.2 ◦F (>38 ◦C to
39 ◦C), and grade 3 if >102.2 F (>39 ◦C). Solicited systemic reac-
ions, unsolicited AEs and all other reactions were considered grade
 if they were noticeable but did not interfere with daily activi-
ies, grade 2 if they interfered with activities, and grade 3 if they
revented daily activity.
.7.  Acceptability and assessment of pain experienced during
accination
All  subjects at vaccination were issued a questionnaire to record
hether they felt the needle puncture, to compare the level of pain
o that of previous seasonal inﬂuenza vaccinations, and whether
hey would elect to receive subsequent vaccinations by the same
ethod. The questionnaire also included a verbal rating scale [21]
o assess the level of pain experienced during vaccination.
.8.  Statistical analysis
Safety  was analyzed in all immunized subjects. Immunogenic-
ty was analyzed in all immunized subjects who provided a blood
ample at day 28. Missing data were not replaced. Statistical cal-
ulations were made using SAS® software, version 8.2 or higher
SAS Institute, Cary, NC). For GMTs and GMT  ratios (GMT at day
8/GMT at day 0), 95% conﬁdence intervals (CIs) were constructed
y standard methods based on the t distribution, assuming a nor-
al  distribution of the log10 titers. A GMT  for an ID or HD vaccine
as considered non-inferior to corresponding GMT  of the SD vac-
ine if the lower limit of the two-sided 95% CI of the ratio of the
wo values (GMTID/GMTSD or GMTHD/GMTSD) was >0.66 and supe-
ior if the lower limit was >1.0. For seroconversion rates, two-sided
5% CIs were constructed using the exact binomial method. For
eroconversion rate differences between vaccine groups, two-sided
symptotic 95% CIs were constructed. A seroconversion rate for an
D or HD vaccine was considered non-inferior to the corresponding
eroconversion rate of the SD vaccine if the lower limit of the two-
ided 95% CI of the difference between the two values was greater
han −10% and superior if the lower limit was >0. In all post hoc
r other comparative analyses, GMT  values were considered sig-
iﬁcantly higher if the lower limit of the two-sided 95% CI of the
atio of the higher to the lower value was >1.0, and seroconversion (2014) 2507–2517 2509
or  seroprotection rates were considered signiﬁcantly higher if the
lower limit of the two-sided 95% CI of the difference between the
higher and lower value was  greater than >0.
3. Results
3.1. Subjects
A  total of 2098 subjects enrolled in the study (Fig. 1). Of these,
1912 were older adults (≥65 years of age) of whom 635 received the
15 g ID vaccine, 635 the 21 g ID vaccine, 319 the SD vaccine, and
320 the HD vaccine. All younger adult subjects received SD vaccine
(n = 186). Sixteen subjects discontinued the study but none were
considered to be for treatment-related reasons. The four older adult
groups had similar baseline characteristics and mean ages (Table 1).
Slightly more than half of the subjects in all groups were women
and most were Caucasian. Most of the subjects in the older adult
groups but less than half of the younger adults had been vaccinated
for seasonal inﬂuenza in the previous year.
3.2. Comparison of ID and SD vaccine immunogenicity in older
adults
In  older adults, the ID vaccines were more immunogenic than
the SD vaccine. Both ID vaccines increased HA titers by approx-
imately 8-fold for the A/H1N1 strain, approximately 3.5-fold for
the A/H3N2 strain, and slightly less than 2-fold for the B strain
(Table 2). In all cases, these post-/pre-vaccination GMT  ratios were
all greater than or equal to the ratios obtained with the SD vac-
cine. Post-vaccination GMTs for both ID vaccines were superior to
those for the SD vaccine for the A/H1N1 and A/H3N2 strains and
were non-inferior for the B strain (Table 3). Seroconversion rates
for both ID vaccines were superior to those for the SD vaccine for
the A/H1N1 and B strains and non-inferior for the A/H3N2 strain
(Table 3 and Fig. 2). All three of these vaccines produced similar
seroprotection rates (Fig. 3).
Post-vaccination GMTs tended to be higher with the 21 g ID
vaccine than with the 15 g ID vaccine (Table 2). However, the
geometric means of the subjects’ individual post-vaccination/pre-
vaccination HI titer ratios for the two  vaccines (Table 2), as well as
the corresponding seroconversion rates and seroprotection rates
(Figs. 2 and 3), were not signiﬁcantly different.
Post-vaccination immunogenicity results for these vaccines did
not differ according to sex or pre-vaccination antibody titer (data
not shown).
3.3. Comparison of HD and SD vaccine immunogenicity in older
adults  and SD vaccine immunogenicity in younger adults
Despite similar pre-vaccination GMTs in the older adult HD and
SD groups, post-vaccination GMTs and seroconversion rates were
all signiﬁcantly higher with the HD vaccine than with the SD vaccine
for all three vaccine strains and seroprotection rates were signiﬁ-
cantly higher for the A/H1N1 and B strains (Table 2; Figs. 2 and 3;
Supplementary Table 1).
Post-vaccination GMTs in elderly adults receiving the HD vac-
cine were also signiﬁcantly higher than in the younger adults
receiving the SD vaccine for the A/H3N2 strain but were signiﬁ-
cantly lower for the A/H1N1 and B strains (Table 2; Supplementary
Table 1). Seroconversion rates in older adults immunized with
the HD vaccine were signiﬁcantly higher than in younger adults
immunized with the SD vaccine for the A/H1N1 strain, were not
signiﬁcantly different for the A/H3N2 strain, and were signiﬁcantly
lower for the B strain (Fig. 2; Supplementary Table 1). Although
there were some pre-vaccination differences between the GMTs
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Older adults ( 65) 
n = 1912  
n = 636* 
1 Non-comp 
n = 636 
n = 634 
1 Non-comp 
1 Vol/non-AE  
2 SAEa 
1 Other AEa 
1 LFU 
3 Vol/non-AE 
n = 627 
n = 319 
n = 317 
1 SAEa 
1 Vol/non-AE  
Randomized 
Day 0 
Vaccinated 
Day 28 
Blood sample 
collected 
Enrolled 
Discontinuations 
Discontinuations 
15 ID 
n = 637 
21 ID 
n = 636 
SD 
n = 319 
HD 
n = 320 
n = 320 
1 LFU 
2 Vol/non-AE 
n = 317 
SD 
n = 186 
n = 186 
n = 185 
1 LFU 
Adults (18 49) 
n = 186 
n = 607 n = 608 n = 304 n = 309 n = 179 
Day 180 
Completed study 
according to protocol 
Other protocol violations
*Includes 1 subject vaccinated with 21 µg ID
 n = 29 n = 19 n = 13 n = 8 n = 6 
Fig. 1. Subject disposition. The study included 1912 older adults (≥65 years of age) who were randomized 2:2:1:1 to receive 15 g ID vaccine, 21 g ID vaccine, SD vaccine
(15 g HA/strain, IM), or HD vaccine (60 g HA/strain, IM)  and 186 adults (18–49 years of age) who  were assigned to receive SD vaccine. All subjects who were vaccinated
were included in the safety analysis and followed-up for 180 days. All subject who  were vaccinated, provided a blood sample on day 28, and completed the study according
to  protocol were included in the immunogenicity analyses. One subject randomized to the 15 g ID group was inadvertently vaccinated with the 21 g ID vaccine and was
include in the immunogenicity analyses for the 21 g ID vaccine. AE, Adverse event; HA, hemagglutinin, ID, intradermal vaccine; IM,  intramuscular vaccine; SAE, serious
adverse event. aUnrelated to vaccination.
Table 1
Demographics of vaccinated subjects.
Older adults Adults
15 g ID (N = 635) 21 g ID (N = 635)a SD (N = 319) HD (N = 320) SD (N = 186)
Sex,  n (%)
Male  272 (42.8) 288 (45.4) 143 (44.8) 137 (42.8) 65 (34.9)
Female  363 (57.2) 347 (54.6) 176 (55.2) 183 (57.2) 121 (65.1)
Age,  years
Mean ± standard deviation 73.1 ± 6.0 72.9 ± 5.9 73.4 ± 5.9 73.0 ± 6.0 32.2 ± 8.5
Range 47–94a 65–96 65–99 65–93 19–50
Ethnicity,  n (%)
Asian  4 (0.6) 3 (0.5) 3 (0.9) 2 (0.6) 0 (0.0)
Black  9 (1.4) 16 (2.5) 13 (4.1) 10 (3.1) 16 (8.6)
Caucasian  604 (95.1) 593 (93.4) 296 (92.8) 300 (93.8) 137 (73.7)
Hispanic  13 (2.0) 20 (3.1) 5 (1.6) 8 (2.5) 28 (15.1)
Other  5 (0.8) 3 (0.5) 2 (0.6) 0 (0.0) 5 (2.6)
Vaccinated  within the past year, n/N (%) 563/633 (88.9) 544/624 (87.2) 280/316 (88.6) 266/317 (83.9) 80/184 (43.5)
Results are for all subjects vaccinated. N is the number of subjects vaccinated in each group. HD, high-dose intramuscular vaccine (60 g HA/strain); ID, intradermal; IM,
intramuscular; SD, standard-dose intramuscular vaccine (15 g HA/strain).
a One subject randomized into the 15 g ID group was inadvertently vaccinated with the 21 g ID vaccine and is included in the latter group for safety and immunogenicity
analyses.
bOne 47-year-old subject was inadvertently randomized into this study group.
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Table  2
Geometric mean titers of vaccinated subjects.
Group Vaccine GMT  A/H1N1 A/H3N2 B
Older adults 15 g ID Pre-vaccination 18.2 (16.8; 19.6)b 104.2 (93.6; 116.0)c 24.8 (23.1; 26.7)
N  = 633 Post-vaccination 163.6 (147.9; 181.0)d 346.5 (319.2; 376.2)d 45.2 (42.3; 48.3)
Ratioa 7.9 (7.2; 8.7) 3.3 (3.0; 3.6) 1.7 (1.6; 1.8)
21  g ID Pre-vaccination 18.6 (17.1; 20.2)e 104.8 (94.2; 116.6) 25.1 (23.3; 27.1)
N  = 624 Post-vaccination 175.7 (159.2; 193.9)e 376.8 (345.8; 410.4) 47.5 (44.4; 50.8)
Ratio 8.3 (7.6; 9.2) 3.5 (3.2; 3.9) 1.8 (1.7; 1.9)
SD  Pre-vaccination 17.7 (15.8; 20.0) 93.5 (80.9; 108.0) 24.7 (22.3; 27.3)
N  = 316 Post-vaccination 109.1 (94.9; 125.5) 281.5 (250.6; 316.2) 43.5 (39.4; 48.1)
Ratio 5.3 (4.7; 6.0) 3.0 (2.6; 3.3) 1.7 (1.5; 1.8)
HD  Pre-vaccination 17.3 (15.4; 19.4) 98.6 (84.1; 115.5) 24.1 (21.7; 26.7)
N  = 317 Post-vaccination 229.8 (201.6; 261.8)* 497.2 (442.4; 558.6)+ 58.9 (53.6; 64.7)*
Ratio 11.5 (10.1; 13.2) 4.9 (4.3; 5.6) 2.3 (2.1; 2.5)
Adults  SD Pre-vaccination 40.5 (32.0; 51.3) 70.1 (56.5; 87.0) 15.3 (13.3; 17.7)
N  = 184 Post-vaccination 337.3 (286.4; 397.3) 382.7 (328.0; 446.5) 69.7 (60.4; 80.5)
Ratio 7.4 (5.9; 9.3) 5.1 (4.1; 6.4) 3.8 (3.2; 4.5)
N is the total number of subjects per group. GMT  values were determined for the number of subjects with at least one valid serology result; unless otherwise indicated,
this was for N subjects. Values in parentheses are 95% conﬁdence intervals. HD, High-dose intramuscular vaccine (60 g HA/strain); ID, intradermal; IM,  intramuscular; SD,
standard-dose intramuscular vaccine (15 g HA/strain).
a Ratio: Geometric mean of individual post-vaccination GMT/pre-vaccination GMT  ratios.
b Value from 630 subjects.
c Value from 632 subjects.
d Value from 631 subjects.
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* Signiﬁcantly higher than the corresponding GMT  for the older adult SD group b
+ Signiﬁcantly higher than the corresponding GMT  for either SD group.
n the older adult HD group and the younger adult SD group, post-
accination seroprotection rates were not signiﬁcantly different for
hese two groups for any strain (Fig. 3; Supplementary Table 1).
Post-vaccination immunogenicity results for these vaccines also
id not differ according to sex or pre-vaccination antibody titer
data not shown).
.4.  Comparison of ID and HD vaccine immunogenicity in older
dults  (post hoc analysis)
Post-vaccination GMTs and seroconversion rates were all sig-
iﬁcantly higher with the HD vaccine than with either of the ID
able 3
nalysis of post-vaccination intradermal vaccine non-inferiority and superiority in older 
Strain Comparison 
A/H1N1 GMTID/GMTSD ratioa
Non-inferior/superior  to SD? 
Seroconversion rate difference (ID − SD, %) 
Non-inferior/superior  to SD? 
A/H3N2 GMTID/GMTSD ratioa
Non-inferior/superior  to SD? 
Seroconversion rate difference (ID − SD, %) 
Non-inferior/superior to SD? 
B  GMTID/GMTSD ratioa
Non-inferior/superior to SD? 
Seroconversion rate difference (ID − SD, %) 
Non-inferior/superior to SD? 
esults are for all subjects vaccinated and with valid immunogenicity results. Values in p
ean titer; SD, standard-dose intramuscular vaccine (15 g HA/strain). The GMT  for an 
imit of the two-sided 95% CI of the GMTID/GMTSD ratio was  >0.66 and superior if the lo
emagglutination inhibition titer <10 and a day 28 titer ≥40 or as a pre-vaccination tite
accine was considered non-inferior to that of the SD vaccine if the lower limit of the two
uperior if the lower limit was >0%.
a Post-vaccination GMT  values and the numbers of subjects used to determine each vaiﬁcantly lower than the corresponding GMT  for the adult SD group.
vaccines  for all three strains (Table 4 and Fig. 2). Seroprotection
rates were also signiﬁcantly higher with the HD vaccine than with
either ID vaccine for the A/H1N1 and B strains but not for the
A/H3N2 strain (Table 4 and Fig. 3).
3.5. Safety and reactogenicity
For  all vaccines, most solicited reactions were generally mild
or moderate and resolved within 3–7 days (data not shown).
Injection-site reactions were reported by similar proportions of
older adult subjects receiving the 15 g (76.5%) or 21 g (77.3%)
ID vaccines, but they were reported more often by subjects
adults.
15 g ID vs. SD 21 g ID vs. SD
N = 633 N = 624
1.50 (1.26; 1.78) 1.61 (1.36; 1.91)
Yes/Yes Yes/Yes
10.5 (4.1; 16.9) 13.4 (7.0; 19.8)
Yes/Yes Yes/Yes
1.23 (1.07; 1.42) 1.34 (1.16; 1.55)
Yes/Yes Yes/Yes
3.5 (−3.0;10.1) 4.2 (−2.4;10.8)
Yes/No Yes/No
1.04 (0.92; 1.17) 1.09 (0.97; 1.23)
Yes/No Yes/No
5.8 (1.7; 10.0) 6.2 (2.0; 10.4)
Yes/Yes Yes/Yes
arentheses are 95% conﬁdence intervals. ID, intradermal vaccine; GMT, geometric
ID vaccine was considered non-inferior to the GMT  of the SD vaccine if the lower
wer limit was >1.0. Seroconversion was deﬁned as either a pre-vaccination serum
r ≥10 and a minimum 4-fold increase at day 28. The seroconversion rate for an ID
-sided 95% CI of the difference between the two values was greater than −10% and
lue are listed in Table 2.
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Fig. 2. Seroconversion rates. The percentage of subjects in each group who  seroconverted for the A/H1N1, A/H3N2, and B strains are shown. Seroconversion in a subject
was  deﬁned by either a pre-vaccination HI titer <1:10 and a day-28 titer ≥1:40 or by a pre-vaccination titer ≥1:10 and a minimum four-fold titer increase at day 28.
HD, High-dose intramuscular vaccine (60 g hemagglutinin/strain); ID, intradermal vaccine (15 ID: 15 g hemagglutinin/strain; 21 ID: 21 g hemagglutinin/strain); SD,
standard-dose intramuscular vaccine (15 g hemagglutinin/strain). * Signiﬁcantly higher than the corresponding rate for the older adult SD group. + Signiﬁcantly higher than
the  corresponding rate for the adult SD group. − Signiﬁcantly lower than the corresponding rate for the adult SD group.
Fig. 3. Seroprotection rates. The pre-vaccination and post-vaccination percentages of subjects having seroprotective hemagglutination inhibition titers for the A/H1N1
( hema
h ; 21 
h er ad
i
H
c
w
(
T
C
R
vA),  A/H3N2 (B), and B (C) strains are shown. Seroprotection was  deﬁned as a 
emagglutinin/strain); ID, intradermal vaccine (15 ID: 15 g hemagglutinin/strain
emagglutinin/strain). * Signiﬁcantly higher than the corresponding rate for the old
mmunized with the ID vaccines than by those receiving the
D (49.5%) or SD (34.5%) IM vaccines (Table 5). Among SD vac-
ine recipients, the proportion reporting injection-site reactions
as higher for younger adults (64.3%) than for older adults
34.5%).
able 4
omparison of HD and ID vaccine immunogenicity in older adults.
Strain Analysis 
A/H1N1 GMTHD/GMTID ratioa
Seroconversion rate difference (HD − ID, %) 
Seroprotection  rate difference (HD − ID, %) 
A/H3N2  GMTHD/GMTID ratio 
Seroconversion rate difference (HD − ID, %) 
Seroprotection rate difference (HD − ID, %) 
B  GMTHD/GMTID ratio 
Seroconversion rate difference (HD − ID, %) 
Seroprotection rate difference (HD − ID, %)
esults are for all older adult subjects vaccinated and with valid immunogenicity results
accine (60 g HA/strain); ID, intradermal vaccine; GMT, geometric mean titer.
a Post-vaccination GMT  ratio. GMT  values and the number of subjects used to determingglutination inhibition titer ≥1:40. HD, high-dose intramuscular vaccine (60 g
ID: 21 g hemagglutinin/strain); SD, standard-dose intramuscular vaccine (15 g
ult SD group.
The  most common injection-site reaction reported with the
ID vaccines was erythema, followed by induration, swelling, and
pruritus, all of which were more common with the ID vac-
cines than with the IM vaccines (i.e. the SD and HD vaccines)
(Fig. 4A). In contrast, injection-site pain was  reported less often
HD vs. 15 g ID HD vs. 21 g ID
1.40 (1.18; 1.66) 1.31 (1.11; 1.55)
9.2 (3.6; 14.7) 6.3 (0.8; 11.8)
5.7 (2.0; 9.5) 3.7 (0.02; 7.3)
1.43 (1.24; 1.65) 1.32 (1.14; 1.53)
13.7 (7.0; 20.4) 13.1 (6.4; 19.8)
1.0 (−0.6; 2.5) 1.6 (−0.02; 3.3)
1.30 (1.16; 1.46) 1.24 (1.10; 1.39)
10.5 (5.0; 16.1) 10.2 (4.6; 15.7)
12.4  (6.4; 18.3) 10.6 (4.7; 16.6)
. Values in parentheses are 95% conﬁdence intervals. HD, High-dose intramuscular
e each value are listed in Table 2.
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Table  5
Safety  summary.
Event Older adults Adults
15 g ID N = 635 21 g ID N = 635 SD N = 319 HD N = 320 SD N = 186
Subjects with at least one, n (%) [95% CI]:
Immediate unsolicited
reactiona
1 (0.2)
[0.0; 0.9]
0 (0.0)
[0.0; 0.9]
1 (0.3)
[0.0; 1.7]
0 (0.0)
[0.0; 1.7]
1 (0.5)
[0.0; 3.0]
Solicited  reactionb
Any 502 (79.1)
[75.7; 82.2]
506/633 (79.9)
[76.6;  83.0]
146 (45.8)
[40.2; 51.4]
194/319 (60.8)
[55.2;  66.2]
multicolumn1@p4pc@139/185
(75.1)
[68.3;  81.2]
Injection-site 486 (76.5)
[73.0; 79.8]
489/633 (77.3)
[73.8;  80.5]
110 (34.5)
[29.3; 40.0]
158/319 (49.5)
[43.9;  55.2]
119/185 (64.3)
[57.0;  71.2]
Systemic  173 (27.2)
[23.8; 30.9]
197/633 (31.1)
[27.5;  34.9]
82 (25.7)
[21.0; 30.9]
116/319 (36.4)
[31.1;  41.9]
101/185 (54.6)
[47.1;  61.9]
Unsolicited  AEc
Any 156 (24.6)
[21.3; 28.1]
179 (28.2)
[24.7; 31.9]
82 (25.7)
[21.0; 30.9]
72 (22.5)
[18.0; 27.5]
77 (41.4)
[34.2; 48.8]
Treatment-related  17 (2.7)
[1.6; 4.3]
15 (2.4)
[1.3; 3.9]
5 (1.6)
[0.5; 3.6]
5 (1.6)
[0.5; 3.6]
6 (3.2)
[1.2; 6.9]
Serious  adverse eventd
Any 34 (5.4)
[3.7; 7.4]
38 (6.0)
[4.3; 8.1]
21 (6.6)
[4.1; 9.9]
16 (5.0)
[2.9; 8.0]
7 (3.8)
[1.5; 7.6]
Treatment-related 0 (0.0)
[0.0; 0.6]
0 (0.0)
[0.0; 0.6]
0 (0.0)
[0.0; 1.1]
0 (0.0)
[0.0; 1.1]
0 (0.0)
[0.0; 2.0]
Results are for all subjects vaccinated and, for solicited reactions, with at least one non-missing value. AE, adverse event; ID, intradermal vaccine; IM,  intramuscular vaccine.
N  values (denominators) different from those shown in the table header are listed in the table body.
a Within 30 min  after vaccination.
b Within 7 days after vaccination.
c Within 28 days after vaccination.
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y older adults immunized with an ID vaccine than by older
dults immunized with the HD vaccine or younger adults immu-
ized with the SD vaccine. Grade-3 erythema and swelling were
eported more often by subjects immunized with an ID vaccine
han by subjects immunized with an IM vaccine, although the
roportions did not appear to differ between the 15 and 21 g
roups.
The proportion of older adult subjects reporting solicited sys-
emic reactions was similar for all vaccines, although myalgia
24.8%) was reported most often by those immunized with the HD
accine (Fig. 4B). The proportions of subjects reporting myalgia,
eadache, and malaise were highest in younger adults receiving
D vaccine.
One subject in three of the groups experienced an immediate
nsolicited reaction (within 30 min  of vaccination): one older adult
ubject immunized with the 15 g ID vaccine reported moderate
izziness lasting one day; one older adult subject immunized with
D vaccine reported moderate jaw pain lasting one day; and one
oung adult immunized with the SD reported a mild sore throat
asting eight days (Table 5).
Only four subjects reported severe treatment-related unso-
icited non-serious AEs. One older adult subject immunized with
he 21 g ID vaccine reported a severe injection-site rash; one
lder adult subject immunized with the HD vaccine reported severe
omiting on the day of vaccination; one older adult subject immu-
ized with the HD vaccine reported severe cough beginning 9 days
fter vaccination; and one younger adult immunized with the SD
accine reported severe diarrhea and vomiting beginning on the
ay of vaccination.
No  treatment-related serious adverse events or treatment-
elated deaths occurred during the study.3.6.  Vaccine acceptability
Vaccination acceptability was similar for all groups (Table 6).
Although roughly two-thirds of the subjects in all groups reported
feeling the needle puncture during vaccination, most of the sub-
jects in each group reported experiencing “no pain” or “hardly any
pain” (range: 77.6% [21 g ID] to 86.2% [HD]). Approximately, 85%
of the subjects in each of the four older adult groups considered the
study injection to be less painful or equally painful than their last
inﬂuenza vaccination, whereas only 65% of the younger adults had
similar opinions.
4.  Discussion
Immune responses to vaccination are weaker in older adults
than in younger adults, and older adults are more susceptible to
the serious health consequences associated with inﬂuenza [1]. As
inﬂuenza-associated hospitalization and mortality rates continue
to increase despite increasing uptake of existing vaccines [2,22],
new vaccines are needed to improve protection against seasonal
inﬂuenza in older adults. Therefore, we  evaluated two  different
strategies that might enhance the immune responses to inﬂuenza
vaccination in older adults: ID vaccination and vaccination with a
high-dose formulation containing four times the standard dose of
HA antigens.
Our primary objective was  to compare two  investigational for-
mulations of ID TIV with the standard-dose IM (SD) vaccine in older
adults. This study showed that the GMTs and seroconversion rates
for the ID vaccines were either non-inferior or superior to those
of the SD vaccine for all three vaccinating strains. Although the ID
vaccines caused minor injection-site reactions in more subjects,
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Fig. 4. Frequency and intensity of solicited injection-site and systemic reactions. Shown is the percent of older adult (15 ID, 21 ID, SD, HD) and adult (SD/Ad) subjects with
solicited injection site reactions (A) and systemic reactions (B) within 7 days of vaccination. Erythema, swelling, induration, and ecchymosis were considered grade 1 if
<2.5  cm, grade 2 if ≥2.5 to <5 cm,  and grade 3 if ≥5 cm.  Fever was  considered grade 1 if ≥99.5 ◦F to ≤100.4 ◦F (≥37.5 ◦C to ≤38 ◦C), grade 2 if >100.4 ◦F to ≤102.2 ◦F (>38 ◦C
to ≤39 ◦C), and grade 3 if >102.2 ◦F (>39 ◦C). All other reactions were considered grade 1 if they were noticeable but did not interfere with daily activities, grade 2 if they
i se int
1 intram
v
t
d
i
I
d
s

t
v
A
i
c
r
p
t
v
mnterfered with activities, and grade 3 if they prevented daily activity. HD, High-do
5  g hemagglutinin/strain; 21 ID: 21 g hemagglutinin/strain); SD, standard-dose 
accine in adults 18 − 49 years of age.
hey were well-tolerated. The study also showed that a standard
ose of vaccine delivered by the ID route in older adults is more
mmunogenic than an equivalent dose delivered by the IM route.
Similar immunogenicity results have been reported with
ntanza/IDﬂu, another split-virion trivalent ID inﬂuenza vaccine
elivered with the same microinjection system [23]. A phase II
tudy in older adults by Holland et al. showed that 15- and 21-
g formulations of Intanza/IDﬂu induced GMTs that were superior
o those induced by the control split-virion IM vaccine for all three
iral strains [15]. This was also conﬁrmed in a phase III study by
rnou et al. examining the 15-g formulation of Intanza/IDﬂu [14].
We also demonstrated that in older adults, the HD vaccine
nduced signiﬁcantly higher antibody responses than the SD vac-
ine induced for all three inﬂuenza strains which extends the
esults of previous studies on HD vaccines [18,24–26]. Though not
art of the original study objectives, post-hoc analysis also showed
hat among older adult subjects, the immune responses to the HD
accine were greater than those induced by either ID vaccine for-
ulation. Despite the greater immunogenicity of the HD vaccine,ramuscular vaccine (60 g hemagglutinin/strain); ID, intradermal vaccine (15 ID:
uscular vaccine (15 g hemagglutinin/strain); SD/Ad, standard-dose intramuscular
some  investigators have questioned its ability to boost the immune
responses of older adults to the levels seen in younger adults vac-
cinated with the SD vaccine. Chen et al. reported that HI antibody
responses are more robust in the younger adults receiving SD vac-
cine than in older adult groups receiving either SD vaccine or
HD vaccine [27]. However, their study included only 63 subjects,
whereas our study included 825 subjects in these three study arms
and found instead that the HD vaccine elicited immune responses
in older adults that, for most measures, were not signiﬁcantly dif-
ferent from or were greater than those elicited by the SD vaccine
in younger adults.
Although  the ID vaccines caused minor injection-site reactions
in more subjects than the other vaccines, they were well-tolerated.
Injection-site pruritus, induration, and swelling were more com-
mon  and slightly more severe with the ID vaccinations than with
the IM vaccinations. Nevertheless, these reactions were mostly
mild or moderate in severity and resolved within 3–7 days. Injec-
tion site erythema, on the other hand, was at least four times more
frequent and was more severe with ID vaccination. The higher rates
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Table  6
Vaccine acceptability.
Question/assessment Older adults Adults
15 g ID N = 633 21 g ID N = 633 SD N = 318 HD N = 319 SD N = 186
When you received your injection, did you feel the needle puncture your skin?
Yes 431 (68.1) 412 (65.1) 204 (64.2) 192 (60.2) 132 (71.0)
No 202 (31.9) 221 (34.9) 110 (34.6) 127 (39.8) 54 (29.0)
In general, would you say that compared to the regular ﬂu shot, this type of injection is:
Less  painful 361 (57.0) 352 (55.6) 132 (41.5) 155 (48.6) 53 (28.5)
The same amount of pain 180 (28.4) 185 (29.2) 135 (42.5) 117 (36.7) 68 (36.6)
More painful 42 (6.6) 42 (6.6) 7 (2.2) 6 (1.9) 6 (3.2)
No opinion/I don’t know 50 (7.9) 54 (8.5) 43 (13.5) 41 (12.9) 59 (31.7)
If you were offered another ﬂu shot, would you receive it by this method?
Yes, with little/no reservation 599 (94.6) 611 (96.5) 307 (96.5) 308 (96.6) 175 (94.1)
Yes, with some/much reservation 24 (3.8) 17 (2.7) 8 (2.5) 5 (1.6) 8 (4.3)
No 10 (1.6) 5 (0.8) 3 (0.9) 5 (1.6) 3 (1.6)
Please circle the number that best describes how much pain you experienced during your ﬂu vaccine injection:
(1) No pain 232 (36.7) 214 (33.8) 147 (46.2) 160 (50.2) 62 (33.3)
(2) Hardly any pain 281 (44.4) 277 (43.8) 125 (39.3) 115 (36.1) 88 (47.3)
(3) Mild pain 91 (14.4) 115 (18.2) 39 (12.3) 36 (11.3) 29 (15.6)
(4) Moderate pain 27 (4.3) 23 (3.6) 6 (1.9) 7 (2.2) 7 (3.8)
(5) Severe pain 2 (0.3) 4 (0.6) 1 (0.3) 0 (0.0) 0 (0.0)
(6) Unbearable pain 0 (0.0) 0 (0.0) 0 (0.0) 1 (0.3) 0 (0.0)
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ntramuscular vaccine.
f injection-site reactions seen with ID vaccination compared with
M vaccination were expected and likely due to the greater sen-
itivity of the skin and the greater visibility of reactions in the
kin. Furthermore, while this study was being performed, US Food
nd Drug Administration guidelines for rating the intensity of ery-
hema, swelling, induration and ecchymosis were modiﬁed so that
 diameter ≥10 cm rather than ≥5 cm is currently considered grade
 [28]. According to these modiﬁed standards, only one subject
0.16%) in the 15 g ID group, three subjects (0.47%) in the 21 g
D group, one subject in the HD group (0.31%), and no subjects in
ither SD group experienced grade-3 erythema. No clinically rele-
ant differences in reactions or AEs were detected between the ID
nd IM vaccines, and there were no obvious safety concerns for any
f the vaccines.
As  expected and as described in previous studies [18,25,26],
olicited injection-site and systemic reactions were more common
n older adults receiving HD vaccine than in those receiving SD vac-
ine. Nevertheless, most of these reactions were self-limited and
f short duration. Unsolicited events were comparable between
hese two older adult groups, and both solicited reactions and unso-
icited AEs were more frequent in the younger adult SD vaccine
ecipients than in either of the older adult groups. SAEs were infre-
uent, occurred with similar frequencies in all groups, and were
onsidered to be unrelated to the study vaccines.
Despite higher rates of injection-site reactions with the ID vac-
ines in this study, older adult vaccinees considered the ID and IM
accines equally acceptable. This agrees well with surveys of vac-
inees performed in several countries, which show a high rate of
atisfaction with Intanza/IDﬂu [29–32]. The acceptability assess-
ents in this study were performed immediately after vaccination,
o they did not consider how delayed injection reactions might
ave inﬂuenced the opinions of the vaccinees. However, we do not
xpect delayed reactions to alter the acceptability because previous
urveys in Turkey and the Czech Republic showed that the accept-
bility of Intanza/IDﬂu was similar when vaccinees were surveyed
mmediately and 8 days after vaccination [31].
As an alternative vaccination method, ID vaccination and the
D Soluvia microinjection system offer several advantages over IM
accination that may  promote acceptance in patients that havestionnaire. Values in parentheses are percentages. ID, Intradermal vaccine; IM,
previously  avoided seasonal inﬂuenza vaccinations. The system
also includes an integrated needle shield, which may reduce the
risk of injury to health-care personnel. Another potential advantage
of ID vaccination was recently reported by Ansaldi et al. who  found
that Intanza/IDﬂu is more effective than SD vaccine at inducing
antibodies that cross-react with heterologous A/H3N2 strains not
included in the vaccines [33]. Thus, the ID route might offer not only
improved but also broader immune responses than the SD vaccine
delivered by the IM route for seasonal inﬂuenza vaccination.
A  number of other ID vaccination methods are currently being
developed as alternatives to vaccination using hypodermic nee-
dles. These include skin patches containing microneedles [34], laser
microporation of the skin prior to placement of a vaccine-laden
patch [35], and pulsed high-velocity microjet injection of extremely
small volumes of liquid in the skin [36]. In one study comparing
transcutaneous seasonal inﬂuenza vaccination, which is presum-
ably achieved via the hair follicles after the skin has been stripped
with tape, to IM vaccination, the transcutaneous route elicited a cel-
lular CD8 response whereas the IM vaccination produced a typical
humoral response [37]. Of note, neutralizing antibodies were pro-
duced only by the IM route. While these techniques have promise
in reducing pain and tissue damage, and in limiting the risks of
transmitting infections and of needle stick injuries, they are all a
few years away from market entry. Concerns have also been raised
among healthcare professionals regarding effectiveness; dose accu-
racy and reliability; conﬁrmation of delivery; delayed onset of
action; and the costs of these systems [38]. The BD Soluvia microin-
jection system offers similar advantages, is already licensed for use
in the US and Europe, and has been shown to be an effective, safe,
and feasible method of ID vaccination.
Although this study showed some promising results, it
measured immunogenicity and not protection against seasonal
inﬂuenza disease. However, given their superior immunogenic-
ity compared to the SD vaccine, it is reasonable to expect that
the ID and HD vaccines might provide greater or longer protec-
tion against infection or lessen the severity of inﬂuenza symptoms
[39,40]. Another limitation of this study was that although vac-
cines were randomly assigned to older adults, younger adults were
neither randomized nor matched for baseline characteristics. This
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ight have introduced confounding imbalances between the dif-
erent groups used to compare the immune responses of older adult
D vaccine recipients to those of younger SD vaccine recipients.
n fact, in addition to the study-required age difference, some dif-
erences in other demographic characteristics also existed for the
ounger group, which included a high percentage of women and
 lower percentage of Caucasians. However, we do not expect that
hese differences had a substantial impact on the study ﬁndings.
In  conclusion, better inﬂuenza vaccines for older adults is an
rgent clinical priority and these results provide support for the
otential advantages of ID and HD vaccines over the SD vac-
ine in older adults. Since both vaccines induced responses in
lderly adults that were similar to or greater than those elicited
y comparator vaccines and were also well-tolerated, these vac-
ine strategies are suitable alternatives to standard IM vaccination.
hether the improved immunogenicity of HD over SD vaccine will
ranslate to improved protection against inﬂuenza in elderly adults
s currently being explored in a multi-year post-licensure study
ClinicalTrials.gov identiﬁer no. NCT01427309).
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